News

German biotechnology company, MorphoSys, was informed by its partner, Swiss global health-care company, Roche, about their decision to discontinue gantenerumab‘s Phase III SCarletRoAD trial for prodromal Alzheimer’s Disease patients. This decision is supported by a recommendation from the Independent Data Monitoring Committee, and by a pre-planned futility assessment. According to Roche, the trial was…

Actavis and Adamas Pharmaceuticals Inc. announced that the US Food and Drug Administration has accepted Namzaric‘s New Drug Application (NDA) as a fixed-dose combination of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, for the treatment of moderate to severe Alzheimer’s Disease in patients stabilized on memantine hydrochloride…

The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded Italian biotechnology company Axxam SpA a $340,485 grant to support the development of novel medication for the treatment of Alzheimer’s disease. The company is exploring drugs based on small molecules with the ability to target inflammation directly. It is the…

A new, sensitive molecular magnetic resonance imaging contrast probe was recently developed by a team of researchers from Northwestern University. The study, entitled “Towards non-invasive diagnostic imaging of early-stage Alzheimer’s disease” was published in Nature Nanotechnology by Kirsten L. Viola, first author of the study, and led…

The head of the Division of Memory Disorders of the University of Alabama at Birmingham (UAB), neurologist David Geldmacher, M.D. recently created the UAB Alzheimer’s Risk Assessment and Intervention Clinic, which is the first of its kind in the country. With the main purpose of helping not…

Eli Lilly and Company and AstraZeneca, who previously partnered to study an investigational treatment for Alzheimer’s disease, have announced the enrollment of the first patient in the study, called AMARANTH. The Phase II/III study aims to evaluate the safety and efficacy of oral beta secretase cleaving…

High levels of testosterone may be connected with higher risk for hallucinations, aggression and other acting-out actions in men that already have Alzheimer’s disease. Lower testosterone levels increase the risk of developing Alzheimer’s disease, according to studies. However, once the onset of Alzheimer’s is established, higher levels of…

A recent study published in the journal eLife suggests that it might be possible to restore lost memories. Over the past century, evidence suggested that long-term memories are expressed in the brain by changes in synaptic connections, which are destroyed in neurodegenerative disorders. However, in a recent news…

A 30 million euro call for research in neurodegenerative disease was recently announced by the EU Joint Programme – Neurodegenerative Disease Research (JPND). The program will receive an additional 10 million in funding from the Horizon 2020 framework program for research and innovation of the European Union. Alzheimer’s, Parkinson’s and other…

The U.S. Food and Drug Administration (FDA) has granted Arjuna Natural Extracts Ltd. a U.S. patent for the company’s turmeric extract formulation, BCM-95 Curcumin, which is expected to become a treatment for patients suffering from Alzheimer’s disease. The patent number 8859020 describes the drugs’s combination of beneficial curcuminoids and turmeric…